NO20060771L - Benzimidazol, benztiazol og benzoksazol derivater og deres anvendelse som LTA4H modulatorer - Google Patents

Benzimidazol, benztiazol og benzoksazol derivater og deres anvendelse som LTA4H modulatorer

Info

Publication number
NO20060771L
NO20060771L NO20060771A NO20060771A NO20060771L NO 20060771 L NO20060771 L NO 20060771L NO 20060771 A NO20060771 A NO 20060771A NO 20060771 A NO20060771 A NO 20060771A NO 20060771 L NO20060771 L NO 20060771L
Authority
NO
Norway
Prior art keywords
group
benztiazole
benzimidazole
lta4h
benzoxazole derivatives
Prior art date
Application number
NO20060771A
Other languages
English (en)
Norwegian (no)
Inventor
Frank Urban Axe
James P Edwards
Jianmei Wei
Cheryl A Grice
Scott D Bembenek
Christopher R Butler
Anne M Fourie
Brad M Savall
Kevin L Tays
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20060771L publication Critical patent/NO20060771L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Materials Engineering (AREA)
  • Rheumatology (AREA)
  • Structural Engineering (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20060771A 2003-07-28 2006-02-17 Benzimidazol, benztiazol og benzoksazol derivater og deres anvendelse som LTA4H modulatorer NO20060771L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49071003P 2003-07-28 2003-07-28
PCT/US2004/024309 WO2005012297A1 (en) 2003-07-28 2004-07-27 Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators

Publications (1)

Publication Number Publication Date
NO20060771L true NO20060771L (no) 2006-04-21

Family

ID=34115427

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20060771A NO20060771L (no) 2003-07-28 2006-02-17 Benzimidazol, benztiazol og benzoksazol derivater og deres anvendelse som LTA4H modulatorer
NO20060823A NO20060823L (no) 2003-07-28 2006-02-20 Benzimidazol, benztiazol og benzoksazol derivater og deres anvendelse som LTA4H modulatorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20060823A NO20060823L (no) 2003-07-28 2006-02-20 Benzimidazol, benztiazol og benzoksazol derivater og deres anvendelse som LTA4H modulatorer

Country Status (28)

Country Link
US (2) US20050043378A1 (de)
EP (2) EP1660492B1 (de)
JP (2) JP2007500703A (de)
KR (2) KR20060054408A (de)
CN (2) CN100591679C (de)
AR (2) AR045730A1 (de)
AT (2) ATE405562T1 (de)
AU (2) AU2004261610B2 (de)
BR (2) BRPI0412345A (de)
CA (2) CA2534228A1 (de)
CY (1) CY1108560T1 (de)
DE (2) DE602004016002D1 (de)
DK (2) DK1660491T3 (de)
ES (2) ES2313079T3 (de)
HR (2) HRP20060041B1 (de)
IL (1) IL173372A (de)
MY (1) MY145080A (de)
NO (2) NO20060771L (de)
NZ (2) NZ544938A (de)
PL (2) PL1660491T3 (de)
PT (2) PT1660492E (de)
RU (2) RU2359970C2 (de)
SG (2) SG129449A1 (de)
SI (2) SI1660491T1 (de)
TW (2) TW200520756A (de)
UA (2) UA87986C2 (de)
WO (2) WO2005012296A1 (de)
ZA (2) ZA200601716B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA87986C2 (uk) * 2003-07-28 2009-09-10 Янссен Фармацевтика Н.В. Бензімідазольні, бензтіазольні та бензоксазольні похідні і їх застосування як lta4h модуляторів
JP2008536825A (ja) * 2005-03-31 2008-09-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ フェニルおよびピリジルｌｔａ４ｈモジュレータ
EP1883402A2 (de) 2005-04-13 2008-02-06 Astex Therapeutics Limited Hydroxybenzamidderivate und ihre verwendung als hsp90-inhibitoren
EP1717235A3 (de) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidine und -pyrrolidine und ihre Verwendung als Liganden für den Histamin H3-Rezeptor
ES2359431T3 (es) * 2005-09-02 2011-05-23 F. Hoffmann-La Roche Ag Derivados de benzooxazol, oxazolopiridina, benzotiazol y tiazolopiridina.
US7402684B2 (en) * 2005-09-21 2008-07-22 Decode Genectics Ehf. Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation
WO2007078335A2 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
CA2634701C (en) * 2005-12-21 2014-07-29 Decode Genetics Ehf Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation
WO2007073405A1 (en) * 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
PL1976828T3 (pl) 2005-12-29 2017-07-31 Celtaxsys, Inc. Pochodne diaminy jako inhibitory hydrolazy leukotrienu a4
EP1987009A1 (de) * 2006-01-30 2008-11-05 Euro-Celtique S.A. Cycloharnstoffverbindung als calciumkanalblocker
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
EP2066800A2 (de) * 2006-08-04 2009-06-10 Decode Genetics EHF Arylaminosäurederivate als inhibitoren zur entzündungsbehandlung
WO2008019284A1 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Phenoxymethylalkyne inhibitors of lta4h for treating inflammation
WO2008019302A1 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Pyrazolylphenyl and pyrrolylphenyl inhibitors of lta4h for treating inflammation
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008044054A2 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Hydroxy-substituted benzoic acid amide compounds for use in therapy
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
ATE482209T1 (de) * 2007-03-08 2010-10-15 Irm Llc Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität
CN101646389A (zh) * 2007-03-30 2010-02-10 松下电工株式会社 活动强度测量装置
PE20091017A1 (es) * 2007-10-31 2009-07-16 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
NZ601350A (en) * 2007-11-16 2013-08-30 Abbvie Inc Method of treating arthritis
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
EP2336125B1 (de) * 2008-04-11 2013-01-09 Janssen Pharmaceutica N.V. Thiazolopyridin-2-yloxy-phenyl- und Thiazolopyrazin-2-yloxy-phenyl-amine als Modulatoren von Leukotrien-A4-hydrolase
PL2294066T3 (pl) 2008-04-28 2015-02-27 Janssen Pharmaceutica Nv Benzimidazole jako inhibitory hydroksylazy prolilowej
US8399465B2 (en) 2009-05-14 2013-03-19 Janssen Pharmaceutica Nv Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase
CN102442962A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-烷基四氮唑的生产方法
CN102442961A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-甲基四氮唑的生产方法
ES2574262T3 (es) 2011-10-25 2016-06-16 Janssen Pharmaceutica, N.V. Formulaciones de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
JP6527851B2 (ja) 2013-03-12 2019-06-05 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素を阻害する方法
AU2014239567B2 (en) 2013-03-14 2017-12-14 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
EP2968264A4 (de) 2013-03-14 2016-11-02 Celtaxsys Inc Inhibitoren der leukotrien-a4-hydrolase
AU2014239585B2 (en) 2013-03-14 2019-04-04 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
EA028921B1 (ru) * 2013-12-17 2018-01-31 Эли Лилли Энд Компани Феноксиэтилы
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
RS59934B1 (sr) 2015-06-09 2020-03-31 Abbvie Inc Modulatori nuklearnih receptora (ror) za lečenje inflamatornih i autoimunih oboljenja
CN110100007B (zh) 2016-12-21 2024-05-28 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的酶的再使用
WO2018114879A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of antibodies
CN107663192B (zh) * 2017-11-03 2019-05-10 梯尔希（南京）药物研发有限公司 一种雷贝拉唑杂质的制备方法
CA3102077A1 (en) 2018-05-31 2019-12-05 Sanjeev AHUJA Method of reducing pulmonary exacerbations in respiratory disease patients
EP3870292A4 (de) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York Kombination von serotonin-spezifischem wiederaufnahmeinhibitor und serotonin-1a-rezeptor-partialagonist zur verminderung von l-dopa-induzierter dyskinesie
SG11202107080VA (en) * 2019-01-11 2021-07-29 Naegis Pharmaceuticals Inc Leukotriene synthesis inhibitors
CN110026557B (zh) * 2019-05-28 2021-08-27 南方科技大学 一种混合固体颗粒重熔的直写装置及成型方法
BR112023009665A2 (pt) * 2020-11-19 2023-12-12 Telo Therapeutics Inc Compostos e composições de molécula pequena
US11932630B2 (en) * 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN113683491A (zh) * 2021-09-01 2021-11-23 王传良 一种4-(2-溴乙基)苯酚的制备方法
CN113735798B (zh) * 2021-09-27 2022-07-12 安徽美致诚药业有限公司 一种盐酸罗沙替丁醋酸酯的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
CA1319144C (en) * 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
IL90337A0 (en) * 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
IT1240598B (it) * 1990-03-13 1993-12-17 Mini Ricerca Scient Tecnolog Derivati amminici ad azione antifungina
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5925654A (en) * 1997-03-12 1999-07-20 G.D. Searle & Co. LTA4 , hydrolase inhibitors
KR20010041346A (ko) * 1998-02-25 2001-05-15 브루스 엠. 에이센, 토마스 제이 데스로저 포스포리파제 ａ2 억제제
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US20040110757A1 (en) * 2002-03-21 2004-06-10 Thomas Arrhenius Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
UA87986C2 (uk) * 2003-07-28 2009-09-10 Янссен Фармацевтика Н.В. Бензімідазольні, бензтіазольні та бензоксазольні похідні і їх застосування як lta4h модуляторів
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
CN101128196B (zh) * 2005-03-16 2013-01-02 Meda制药有限及两合公司 用于治疗呼吸系统疾病的抗胆碱能药和白三烯受体拮抗剂的组合
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof

Also Published As

Publication number Publication date
RU2359970C2 (ru) 2009-06-27
SI1660492T1 (sl) 2009-02-28
HK1090359A1 (en) 2006-12-22
IL173372A0 (en) 2006-06-11
NO20060823L (no) 2006-03-15
DE602004016002D1 (de) 2008-10-02
ES2313079T3 (es) 2009-03-01
SG129449A1 (en) 2007-02-26
ZA200601716B (en) 2007-05-30
HRP20060039A2 (en) 2006-08-31
HK1092790A1 (en) 2007-02-16
AU2004261610B2 (en) 2010-05-20
US20050043379A1 (en) 2005-02-24
EP1660491A1 (de) 2006-05-31
DE602004015620D1 (de) 2008-09-18
US20050043378A1 (en) 2005-02-24
SI1660491T1 (sl) 2009-02-28
JP2007500703A (ja) 2007-01-18
KR20060057593A (ko) 2006-05-26
PT1660491E (pt) 2008-10-10
EP1660492B1 (de) 2008-08-20
AU2004261628A1 (en) 2005-02-10
PL1660492T3 (pl) 2009-01-30
RU2373204C2 (ru) 2009-11-20
ATE403654T1 (de) 2008-08-15
TW200523255A (en) 2005-07-16
CN1860117A (zh) 2006-11-08
RU2006102510A (ru) 2006-07-27
ZA200601720B (en) 2007-11-28
RU2006102508A (ru) 2006-07-27
AU2004261610A1 (en) 2005-02-10
ATE405562T1 (de) 2008-09-15
UA87986C2 (uk) 2009-09-10
TWI362383B (en) 2012-04-21
NZ544970A (en) 2009-02-28
BRPI0413072A (pt) 2006-10-03
NZ544938A (en) 2009-05-31
CN100591679C (zh) 2010-02-24
SG130192A1 (en) 2007-03-20
CN1856490A (zh) 2006-11-01
UA82888C2 (en) 2008-05-26
DK1660491T3 (da) 2008-11-10
DK1660492T3 (da) 2008-11-03
TW200520756A (en) 2005-07-01
HRP20060041B1 (hr) 2014-06-06
KR20060054408A (ko) 2006-05-22
EP1660492A1 (de) 2006-05-31
JP2007500706A (ja) 2007-01-18
WO2005012296A1 (en) 2005-02-10
AR045730A1 (es) 2005-11-09
IL173372A (en) 2010-11-30
JP4726238B2 (ja) 2011-07-20
CY1108560T1 (el) 2014-04-09
EP1660491B1 (de) 2008-08-06
AU2004261628B2 (en) 2011-05-12
WO2005012297A1 (en) 2005-02-10
MY145080A (en) 2011-12-15
CA2534228A1 (en) 2005-02-10
ES2311858T3 (es) 2009-02-16
HRP20060041A2 (en) 2006-11-30
BRPI0412345A (pt) 2006-10-03
PT1660492E (pt) 2008-11-13
WO2005012297A9 (en) 2007-01-04
AR045729A1 (es) 2005-11-09
CA2534212A1 (en) 2005-02-10
PL1660491T3 (pl) 2009-01-30
KR101149379B1 (ko) 2012-06-28

Similar Documents

Publication Publication Date Title
NO20060771L (no) Benzimidazol, benztiazol og benzoksazol derivater og deres anvendelse som LTA4H modulatorer
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
FI970246A7 (fi) Dihydrobentsofuraanit
TW200605884A (en) CETP inhibitors
BG101422A (bg) Бензоксазолни производни като бронхоразширяващи средства
ECSP066967A (es) Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos
NO20072963L (no) 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
PT1200426E (pt) Tieno-3-il-sulfonilamino (tio) carbonil-triazolino (ti) onas substituidas
NO20022124L (no) Imidazopyridinderivater som fosfodiesterase VII-inhibitorer
ATE258930T1 (de) Dihydrobenzifurane
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
ATE399168T1 (de) Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren
PT1098885E (pt) Compostos de imidazole e sua utilizacao como inibidores da desaminase de adenosina
ATE308541T1 (de) 2-amino-4-heteroarylethyl-thiazolinderivate und ihre verwendung als hemmstoffe der induzierbaren no-synthase
NO20033131L (no) Anvendelse av 2-amino-4-pyridylmetyl-tiazolinderivater som inhibitorer forinduktibel NO-syntase
NO20061045L (no) Imidazolderivater
ATE488510T1 (de) Heterocyclische derivate, deren herstellung und therapeutische verwendung
EA200600608A1 (ru) Производные имидазопиридина как ингибиторы индуцируемой no-синтазы
TNSN06456A1 (en) Cetp inhibitors
SE9904676D0 (sv) Novel compounds
NO20081083L (no) Antitumorforbindelser
NO20061099L (no) Nye forbindelser
BR0317126A (pt) Derivados de indol e o uso dos mesmos como ligantes de 5-ht
ATE236887T1 (de) Arylsulfonamid-substituierte benzimidazolderivate und ihre verwendung als tryptase-inhibitoren
ATE340175T1 (de) Imidazo(4,5-böchinolinderivate und ihre verwendung als inhibitoren der induzierbaren no- synthase

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application